COMP <GO>
TATT vs TMO // PIOTROSKI F-SCORE QUALITY
TAT Technologies Ltd. (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: TATT 5
— TMO 7
▲ PIOTROSKI F-SCORE QUALITY LEADER: TMO
LAST: $33.50 (+2.89%) • MKT CAP: $434.9M
piotroski-score
7/9
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
piotroski-score
8/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TATT VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TATT | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 24.80% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.00% | 9.30% | +1.70 | TATT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 14.0x | 30.4x | -16.40 | TATT | /valuation <GO> |
| Free Cash Flow Yield | 0.92% | 2.40% | -1.48 | TMO | /fcf-yield <GO> |
| Operating Margin | 10.60% | 17.40% | -6.80 | TMO | /operating-margins <GO> |
| Net Profit Margin | 9.40% | 15.10% | -5.70 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 17.00% | 3.90% | +13.10 | TATT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.20 | 4.50 | +2.70 | TATT | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.1 | 62.9 | -22.82 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.8x | 36.3x | -14.50 | TATT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $434.9M | $262.22B | -$261.78B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TATT REV | TMO REV | TATT GROSS % | TMO GROSS % | TATT FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $178.0M | $44.56B | 24.8% | — | $4.0M | $6.29B |
| FY 2024 | $152.1M | $42.88B | 21.7% | — | -$10.9M | $7.27B |
| FY 2023 | $113.8M | $42.86B | — | — | $2.3M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TATT // BETA —
TMO // BETA 0.94